Unlock regulatory insights with Watson. Learn More
Return to Docket

Designate Opana® ER (oxymorphone hydrochloride) Extended-release Tablets as a Second RLD for the Purposes of Submitting an ANDA

Type: Non-Rule Making
KeyWord(s) Opana®, Oxymorphone, Hydrochloride, Tablets, NDA 201655, CDER
Short title Designate Opana® ER (oxymorphone hydrochloride) Extended-release Tablets as a Second RLD for the Purposes of Submitting an ANDA
Docket Item Code P
Center CDER

Supporting Documents (0)

Your search found no documents. Click here to search more.